LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Pharmacogenomic; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 31 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 02 Mar 2017 Planned End Date changed from 1 Dec 2018 to 1 Apr 2017.